[CAS NO. 1366302-52-4] PSMA-11

Name: PSMA-11
Brand: Arctom Scientific
SKU: HY-125399

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1366302-52-4]

Store

Catalog

HY-125399

Brand

MCE

CAS

1366302-52-4

DESCRIPTION [1366302-52-4]

Overview

MDL	-
Molecular Weight	946.99
Molecular Formula	C44H62N6O17
SMILES	OC(CN(CCN(CC(O)=O)CC1=CC(CCC(O)=O)=CC=C1O)CC2=CC(CCC(NCCCCCC(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)=CC=C2O)=O

For research use only. We do not sell to patients.

Summary

PSMA-11 is a positron emission tomography (PET) tracer. PSMA-11 detects prostate cancer relapses and metastases by binding to the extracellular domain of prostate-specific membrane antigen (PSMA) ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03181867	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Prostate Neoplasms\|Prostatic Cancer\|Prostate Cancer\|Cancer Of Prostate\|Metastatic Prostate Cancer	August 3, 2017	Phase 2
NCT04976257	Ryan Kohlbrenner, MD\|Radiological Society of North America\|University of California, San Francisco	Prostate Adenocarcinoma\|Prostate Carcinoma\|Stage IIC Prostate Cancer AJCC v8\|Stage III Prostate Cancer AJCC v8\|Stage IIIA Prostate Cancer AJCC v8\|Stage IIIB Prostate Cancer AJCC v8\|Stage IIIC Prostate Cancer AJCC v8\|Stage IV Prostate Cancer AJCC v8\|Stage IVA Prostate Cancer AJCC v8\|Stage IVB Prostate Cancer AJCC v8	October 13, 2021	Early Phase 1
NCT02918357	University of California, San Francisco	Prostate Cancer	September 15, 2016	Phase 2\|Phase 3
NCT03515577	Jonsson Comprehensive Cancer Center	Recurrent Prostate Carcinoma	April 12, 2019	Phase 2
NCT04800068	Mayo Clinic	Prostate Cancer
NCT03803475	Thomas Hope\|University of California, San Francisco	Prostate Cancer	October 11, 2018	Phase 3
NCT03353740	Thomas Hope\|University of California, San Francisco	Prostate Cancer	September 20, 2017	Phase 3
NCT04825652	Advanced Accelerator Applications	Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT04050215	Jonsson Comprehensive Cancer Center	Biochemically Recurrent Prostate Carcinoma\|Metastatic Prostate Carcinoma\|Prostate Adenocarcinoma\|Prostate Carcinoma\|PSA Level Greater Than Fifty\|PSA Progression\|Stage IV Prostate Cancer AJCC v8\|Stage IVA Prostate Cancer AJCC v8\|Stage IVB Prostate Cancer AJCC v8	April 2, 2018	Phase 2
NCT03463889	University of California, San Francisco	Thyroid Gland Carcinoma	March 19, 2018	Phase 2
NCT04483414	Dana Mathews\|University of Texas Southwestern Medical Center	Prostate Cancer\|Prostate Cancer Metastatic\|Prostate Cancer Metastatic to Bone	March 19, 2021	Phase 2
NCT02919111	University of California, San Francisco	Prostate Cancer	September 23, 2016	Phase 2\|Phase 3
NCT03582774	Jonsson Comprehensive Cancer Center\|National Cancer Institute (NCI)	Recurrent Prostate Carcinoma	July 12, 2018	Phase 3
NCT04264208	Andrei Iagaru\|National Institutes of Health (NIH)\|National Cancer Institute (NCI)\|Stanford University	Prostate Cancer	February 5, 2020	Phase 2
NCT04179968	Dana Mathews\|University of Texas Southwestern Medical Center	Prostate Cancer\|Prostate Cancer Metastatic	January 27, 2020	Phase 2
NCT04310540	Mayo Clinic	Hepatocellular Carcinoma	June 5, 2020	Phase 2
NCT03183544	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Prostatic Neoplasm	January 24, 2019	Phase 1
NCT04147494	Jonsson Comprehensive Cancer Center\|Society of Nuclear Medecine and Molecular Imaging	Breast Carcinoma\|Colon Carcinoma\|Esophageal Carcinoma\|Gastric Carcinoma\|Head and Neck Carcinoma\|Kidney Carcinoma\|Lung Carcinoma\|Ovarian Carcinoma\|Pancreatic Carcinoma\|Solid Neoplasm\|Uterine Corpus Cancer	November 5, 2019	Early Phase 1
NCT04282824	Jonsson Comprehensive Cancer Center	Prostate Carcinoma	June 5, 2019	Early Phase 1
NCT04216134	City of Hope Medical Center\|National Cancer Institute (NCI)	Biochemically Recurrent Prostate Carcinoma	December 12, 2019	Phase 1
NCT04846894	Jin-Sook Ryu\|Asan Medical Center	Prostate Cancer	April 13, 2021	Not Applicable
NCT03762759	Emory University\|Telix International Pty Ltd\|National Cancer Institute (NCI)	Prostate Adenocarcinoma	May 10, 2019	Phase 2
NCT03857087	University of California, San Francisco\|Radiological Society of North America	Ovarian Carcinoma	April 2, 2018
NCT03949517	Andrei Iagaru\|General Electric\|Stanford University	Prostate Cancer	April 9, 2019	Phase 1\|Phase 2
NCT05034562	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Metastatic Prostate Carcinoma\|Recurrent Prostate Carcinoma\|Stage IV Prostate Cancer AJCC v8\|Stage IVA Prostate Cancer AJCC v8\|Stage IVB Prostate Cancer AJCC v8	September 26, 2022	Phase 2
NCT03768349	Mayo Clinic	Prostate Cancer	January 3, 2019	Early Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 105.60 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.0560 mL	5.2799 mL	10.5598 mL
5 mM	0.2112 mL	1.0560 mL	2.1120 mL
10 mM	0.1056 mL	0.5280 mL	1.0560 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Demirci E, et al. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Nucl Med Commun. 2016 Nov;37(11):1169-79.